Literature DB >> 16444460

Recurrent thrombosis in patients with deep vein thrombosis and/or venous thromboembolism associated with anticardiolipin antibodies.

José Maria Pereira de Godoy1, Moacir Fernandes de Godoy, Domingo Marcolino Braile.   

Abstract

Anticardiolipin antibodies represent one of the main hypercoagulation states associated with venous thromboembolism. The aim of this work was to evaluate symptomatic recurrent thrombosis in patients with anticardiolipin antibodies and deep vein thrombosis of the lower limbs with or without thromboembolism. Sixty patients who suffered from deep vein thrombosis were observed for a 5-year period, whether they had anticardiolipin antibodies or not. The group was made up of 34 females and 26 males with ages ranging from 13 to 73 years. All were diagnosed with deep vein thrombosis by means of phlebography and were tested for anticardiolipin antibodies by use of the ELISA method. The symptomatic signs of recurrent thrombosis were evaluated during this period. In total, 56.6% of the group were considered above normal for anticardiolipin antibodies, 25% positive, another 31.6% borderline, and 43.4% negative. Patients were tested positive when the anticardiolipin antibody count was >15 units/mL, borderline between 10 and 15 units/mL, and normal when <10 units/mL. The method of relative risk was used for statistical analysis of the results. Four positive patients, 1 borderline, and 1 normal patient had recurrent events of thrombosis. In the statistical analysis the relative risk for recurrent thrombosis in the positive patients was 6.0; CI 95%; 1.2 to 29.5. In conclusion patients with deep vein thrombosis who are positive for anticardiolipin antibodies present a higher risk of recurrent thrombosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444460     DOI: 10.1177/000331970605700111

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  7 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

2.  SARS-CoV-2 gamma variant and chronic arterial insufficiency due to late arterial thrombosis.

Authors:  Jose Maria Pereira de Godoy; Guilherme Marum; Henrique Amorim Santos; Mariana Orate Menezes da Silva; Fernanda Cordeiro da Silva
Journal:  Int J Health Sci (Qassim)       Date:  2022 Jul-Aug

3.  Increased prevalence of deep vein thrombosis and mortality in patients with Covid-19 at a referral center in Brazil.

Authors:  Jose Maria Pereira de Godoy; Gleison Juliano da Silva Russeff; Carolina Hungaro Cunha; Debora Yuri Sato; Desirée Franccini Del Frari Silva; Henrique Jose Pereira de Godoy; Mariana Orate Menezes da Silva; Henrique Amorim; Marina Morães Lopes Soares; Maria de Fatima Guerreiro Godoy
Journal:  Phlebology       Date:  2021-09-08       Impact factor: 1.740

4.  Factors affecting the recurrence in patients with venous thromboembolism: A retrospective cohort study.

Authors:  Yasemin Ateş; Züleyha Bingöl; Gülfer Okumuş; Orhan Arseven
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-07-26       Impact factor: 0.332

5.  Thromboangiitis obliterans in two brothers.

Authors:  Qi-Lin Li; Dan-Hua He; Yong-Hua Huang; Mu Niu
Journal:  Exp Ther Med       Date:  2013-06-14       Impact factor: 2.447

Review 6.  Advances in the Research on Anticardiolipin Antibody.

Authors:  Dan Wang; Wenxin Lv; Shichang Zhang; Jiexin Zhang
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

7.  Mortality of Patients Infected by COVID-19 with and without Deep-Vein Thrombosis.

Authors:  Jose Maria Pereira de Godoy; Gleison Juliano da Silva Russeff; Carolina Hungaro Costa; Debora Yuri Sato; Desirée Franccini Del Frari Silva; Maria de Fatima Guerreiro Godoy; Henrique Jose Pereira de Godoy; Paulo César Espada
Journal:  Medicines (Basel)       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.